Published in J Immunol on December 15, 1992
Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med (1993) 1.81
Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med (1995) 1.45
Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. Proc Natl Acad Sci U S A (1994) 1.38
Costimulator deficient antigen presentation by an endothelial cell line induces a nonproliferative T cell activation response without anergy. J Exp Med (1993) 1.30
Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells. Proc Natl Acad Sci U S A (1996) 1.25
Tolerogenicity of resting and activated B cells. J Exp Med (1994) 1.25
B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Invest (2001) 1.24
Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor. Proc Natl Acad Sci U S A (1993) 1.03
Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci U S A (1995) 0.94
Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation. Immunology (1999) 0.87
Activation of CD4+ T lymphocytes form interleukin 2-deficient mice by costimulatory B7 molecules. Proc Natl Acad Sci U S A (1996) 0.86
CD28-B7 costimulatory blockade by CTLA4Ig delays the development of retrovirus-induced murine AIDS. J Virol (1998) 0.85
The costimulatory molecule B7 is expressed in the medullary region of the murine thymus. Immunology (1994) 0.83
Influence of CD28 co-stimulation on cytokine production is mainly regulated via interleukin-2. Immunology (1994) 0.81
Enhancement of antigen-presenting ability of B lymphoma cells by partial inhibition of protein synthesis through inducing B7-1 expression. Immunology (1997) 0.80
Reduced lysis by CD8+ cytotoxic T cells in mixed lymphocyte reactions induced via CD4+ T cells exposed to chemically modified antigen presenting cells. Immunology (1995) 0.77
The defective antigen-presenting activity of murine fetal macrophage cell lines. Immunology (1997) 0.77
Histocompatibility-linked immune response genes. Science (1972) 16.79
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
CD4+CD25high regulatory cells in human peripheral blood. J Immunol (2001) 11.25
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
The regulatory influence of activated T cells on B cell responses to antigen. Adv Immunol (1972) 9.43
Genetic control of specific immune responses. Adv Immunol (1969) 8.81
Properties of antibodies cytophilic for macrophages. J Exp Med (1966) 8.64
Cell interactions between histoincompatible T and B lymphocytes. VII. Cooperative responses between lymphocytes are controlled by genes in the I region of the H-2 complex. J Exp Med (1975) 7.64
Methadone maintenance treatment in opiate dependence: a review. BMJ (1994) 7.37
Cell selection by antigen in the immune response. Adv Immunol (1969) 6.05
Role of maintenance treatment in opioid dependence. Lancet (1999) 6.02
The function and interrelationships of T-cell receptors, Ir genes and other histocompatibility gene products. Transplant Rev (1975) 5.88
Carrier function in anti-hapten immune responses. I. Enhancement of primary and secondary anti-hapten antibody responses by carrier preimmunization. J Exp Med (1970) 5.71
Genetic control of immune responses in vitro. V. Stimulation of suppressor T cells in nonresponder mice by the terpolymer L-glutamic acid 60-L-alanine 30-L-tyrosine 10 (GAT). J Exp Med (1974) 5.55
A hypothesis to relate the specificity of T lymphocytes and the activity of I region-specific Ir genes in macrophages and B lymphocytes. J Immunol (1978) 5.07
Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br J Addict (1992) 5.02
Role of MHC gene products in immune regulation. Science (1981) 4.84
The behavior of hapten-poly-L-lysine conjugates as complete antigens in genetic responder and as haptens in nonresponder guinea pigs. J Exp Med (1966) 4.58
The effects of adolescent cannabis use on educational attainment: a review. Addiction (2000) 4.32
Functional specificity of thymus- dependent lymphocytes. Science (1977) 4.31
Carrier function in anti-hapten antibody responses. 3. Stimulation of antibody synthesis and facilitation of hapten-specific secondary antibody responses by graft-versus-host reactions. J Exp Med (1971) 4.29
Prevalence, comorbidity, disability and service utilisation. Overview of the Australian National Mental Health Survey. Br J Psychiatry (2001) 4.24
Cell interactions between histoincompatible T and B lymphocytes. The H-2 gene complex determines successful physiologic lymphocyte interactions. Proc Natl Acad Sci U S A (1973) 4.12
Improving the quality of the cannabis debate: defining the different domains. BMJ (2000) 4.06
Cell interactions between histoincompatible T and B lymphocytes. IV. Involvement of the immune response (Ir) gene in the control of lymphocyte interactions in responses controlled by the gene. J Exp Med (1973) 4.05
Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol (2001) 4.05
The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction (1995) 4.02
A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. Scand J Immunol (1981) 3.85
B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A (1991) 3.84
Immunosuppressive factor(s) extracted from lymphoid cells of nonresponder mice primed with L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT). J Immunol (1976) 3.64
ICOS is critical for CD40-mediated antibody class switching. Nature (2001) 3.63
The immune response genes of the major histocompatibility complex. Immunol Rev (1978) 3.61
The effect of the amount of mycobacterial adjuvants on the immune response of strain 2, strain 13 and Hartley strain guinea pigs to DNP-PLL and DNP-GL. J Immunol (1969) 3.53
The injecting and sexual behaviour of intravenous drug users in Sydney. Med J Aust (1990) 3.47
Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med (1984) 3.36
Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc Natl Acad Sci U S A (1993) 3.27
B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity (1997) 3.22
Antigen- and receptor-driven regulatory mechanisms. IV. Idiotype-bearing I-J+ suppressor T cell factors induce second-order suppressor T cells which express anti-idiotypic receptors. J Exp Med (1980) 3.21
Genetic control of specific immune suppression. II. H-2-linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid50-L-tyrosine50 (GT). J Exp Med (1975) 3.17
Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol (1991) 3.12
Regulation by the H-2 gene complex of macrophage-lymphoid cell interactions in secondary antibody responses in vitro. J Exp Med (1976) 3.10
The reliability and validity of a scale to measure HIV risk-taking behaviour among intravenous drug users. AIDS (1991) 3.05
Secondary antibody responses in haptenic systems: cell population selection by antigen. J Immunol (1967) 3.01
Genetic control of immune responses in vitro. 3. Tolerogenic properties of the terpolymer L-glutamic acid 60-L-alanine30-L-tyrosine10 (GAT) for spleen cells from nonresponder (H-2s and H-2q) mice. J Exp Med (1974) 3.01
The Swiss heroin trials: testing alternative approaches. BMJ (1998) 3.00
Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol (2001) 2.97
Methadone maintenance reduces injecting in prison. BMJ (1996) 2.94
Linkage between the poly-L-lysine gene and the locus controlling the major histocompatibility antigens in strain 2 guinea pigs. Proc Natl Acad Sci U S A (1970) 2.89
Complementation of H-2-linked Ir genes in the mouse. Proc Natl Acad Sci U S A (1975) 2.88
Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science (1993) 2.78
Genetic control of specific immune suppression. I. Experimental conditions for the stimulation of suppressor cells by the copolymer L-glutamic acid50-L-tyrosine50 (GT) in nonresponder BALB/c mice. J Exp Med (1975) 2.78
Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci U S A (1993) 2.76
Characterization of CTLA-4 structure and expression on human T cells. J Immunol (1993) 2.68
The histocompatibility-linked immune response genes. Adv Cancer Res (1975) 2.64
Suppressor cells and immunoregulation. Annu Rev Immunol (1984) 2.63
Genetic control of immune responsiveness to a glutamic acid, alanine, tyrosine copolymer in mice. I. Linkage of responsiveness to H-2 genotype. J Immunol (1971) 2.60
Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc Natl Acad Sci U S A (1992) 2.56
Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature (1992) 2.55
Carrier function in anti-hapten immune responses. II. Specific properties of carrier cells capable of enhancing anti-hapten antibody responses. J Exp Med (1970) 2.54
Calculating standard drink units: international comparisons. Br J Addict (1991) 2.53
Mechanisms of regulation of cell-mediated immunity. II. Induction and suppression of delayed-type hypersensitivity to azobenzenearsonate-coupled syngeneic cells. J Immunol (1978) 2.52
Shared idiotypic determinants on antibodies and T-cell-derived suppressor factor specific for the random terpolymer L-glutamic acid60-L-alanine30-L-tyrosine10. J Exp Med (1979) 2.51
Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. Addiction (2001) 2.49
The distribution of antigenic and nonantigenic compounds within draining lymph nodes. Lab Invest (1966) 2.49
Biological behavior of human breast carcinoma-associated antigens expressed during cellular proliferation. Cancer Res (1983) 2.46
Antigen binding and capping by lymphocytes of genetic nonresponder mice. J Exp Med (1972) 2.46
Nobel laureates' letter to President Bush. Washington Post (2001) 2.43
Hapten-specific T-cell responses to 4-hydroxy-3-nitrophenyl acetyl. II. Demonstration of idiotypic determinants on suppressor T cells. J Exp Med (1979) 2.40
The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J Immunol (1988) 2.39
Genetic control of specific immune suppression. IV. Responsiveness to the random copolymer L-glutamic acid50-L-tyrosine50 induced in BALB/c mice by cyclophosphamide. J Exp Med (1976) 2.39
Radioresistance of carrier-specific helper thymus-derived lymphocytes in mice. Proc Natl Acad Sci U S A (1972) 2.35
Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science (1997) 2.33
Antihapten antibody specificity and L chain type. J Exp Med (1967) 2.33
Production of human hybridomas secreting antibodies to measles virus. Nature (1980) 2.32
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Heroin overdose: the case for take-home naloxone. BMJ (1996) 2.25
Heroin overdose: causes and consequences. Addiction (2001) 2.23
Overdose among heroin users in Sydney, Australia: I. Prevalence and correlates of non-fatal overdose. Addiction (1996) 2.20
The biologic significance of alloreactivity. The ontogeny of T-cell sets specific for alloantigens or modified self antigens. J Exp Med (1978) 2.20
Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells. J Immunol (2000) 2.16
Studies on the effect of the carrier molecule on antihapten antibody synthesis. I. Effect of carrier on the nature of the antibody synthesized. J Exp Med (1966) 2.16
A sonographic screening method for Down syndrome. Am J Obstet Gynecol (1987) 2.16
Hapten-specific T-cell responses to 4-hydroxy-3-nitrophenyl acetyl. I. Genetic control of delayed-type hypersensitivity by VH and I-A-region genes. J Exp Med (1979) 2.14
Immunosuppressive factor(s) specific for L-glutamic acid50-L-tyrosine50 (GT) II. Presence of I-J determinants on the GT-suppressive factor. J Exp Med (1977) 2.12
Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. V. Role of idiotypes in the suppressor pathway. J Exp Med (1980) 2.11
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science (1994) 2.10
Immunosuppressive factor(s) specific for L-glutamic acid50-L-tyrosine50 (GT). III. Generation of suppressor T cells by a suppressive extract derived from GT-primed lymphoid cells. J Exp Med (1977) 2.08
Properties of macrophage receptors for cytophilic antibodies. Br J Exp Pathol (1966) 2.07
The I-J subregion codes for determinats on suppressor factor(s) which limit the contact sensitivity response to picryl chloride. J Exp Med (1977) 2.07